Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$120,000.00
Prophylactic strategies to reduce incidence of Pneumocystis pneumonia in individuals with cancer and autoimmune rheumatic inflammatory disease in Ontario, Canada
EF 2024-25
Résumé
Pneumocystis pneumonia is a deadly lung infection that can happen in people with diseases affecting the immune system, including cancer and autoimmune disease (such as lupus). An antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can be taken to prevent Pneumocystis pneumonia, but it can have severe side effects. To avoid side effects, we only want to give TMP-SMX in people where the benefit is more than the risk, which can be difficult to know. My studies will help sort this out.
I will use health data from people older than 65 years living in Ontario with cancer or autoimmune disease between 2005-2023 to answer 3 questions.
In my first study, I will test if certain medications that affect the immune system cause people to get more Pneumocystis pneumonia. I will compare people taking immune medications who are and are not receiving TMP-SMX to see if Pneumocystis pneumonia is more common in the group without TMP-SMX. I will repeat this study with common drugs (such as steroids) to find the risk for Pneumocystis pneumonia with these drugs. I will also see how many side effects people have with TMP-SMX.
In my second study, I will test which TMP-SMX antibiotic dose is the best for preventing Pneumocystis pneumonia. There are three doses of TMP-SMX, but we do not know which is the most effective and safest. Like in study 1, I will look at people taking TMP-SMX at one of the three recommended dose and compare who develops Pneumocystis pneumonia and side effects.
The last study tests if a white blood cell, called lymphocyte, can tell us who should get TMP-SMX. I will look at people who had a lymphocyte blood test and compare people on TMP-SMX or not to see if lymphocyte count can predict who will will develop Pneumocystis pneumonia.
These studies will let doctors, scientists, and patients know if and when TMP-SMX should be used in patients with cancer or autoimmune disease, to reduce the risk of Pneumocystis pneumonia and avoid harmful side effects.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
518320
Name
Arbiv Omri A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Health systems / services
Prcname2
Doctoral Research Awards - B
Projecttitle
Prophylactic strategies to reduce incidence of Pneumocystis pneumonia in individuals with cancer and autoimmune rheumatic inflammatory disease in Ontario, Canada
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Administrative Data; Autoimmune Inflammatory Rheumatic Disease; Bayesian Methods; Cancer; Causal Inference; Epidemiology; Health Services Research; Infectious Diseases; Pneumocystis Pneumonia; Trimethoprim-Sulfamethoxazole
Abstract
Pneumocystis pneumonia is a deadly lung infection that can happen in people with diseases affecting the immune system, including cancer and autoimmune disease (such as lupus). An antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can be taken to prevent Pneumocystis pneumonia, but it can have severe side effects. To avoid side effects, we only want to give TMP-SMX in people where the benefit is more than the risk, which can be difficult to know. My studies will help sort this out.
I will use health data from people older than 65 years living in Ontario with cancer or autoimmune disease between 2005-2023 to answer 3 questions.
In my first study, I will test if certain medications that affect the immune system cause people to get more Pneumocystis pneumonia. I will compare people taking immune medications who are and are not receiving TMP-SMX to see if Pneumocystis pneumonia is more common in the group without TMP-SMX. I will repeat this study with common drugs (such as steroids) to find the risk for Pneumocystis pneumonia with these drugs. I will also see how many side effects people have with TMP-SMX.
In my second study, I will test which TMP-SMX antibiotic dose is the best for preventing Pneumocystis pneumonia. There are three doses of TMP-SMX, but we do not know which is the most effective and safest. Like in study 1, I will look at people taking TMP-SMX at one of the three recommended dose and compare who develops Pneumocystis pneumonia and side effects.
The last study tests if a white blood cell, called lymphocyte, can tell us who should get TMP-SMX. I will look at people who had a lymphocyte blood test and compare people on TMP-SMX or not to see if lymphocyte count can predict who will will develop Pneumocystis pneumonia.
These studies will let doctors, scientists, and patients know if and when TMP-SMX should be used in patients with cancer or autoimmune disease, to reduce the risk of Pneumocystis pneumonia and avoid harmful side effects.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Arbiv, Omri A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~